Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 6Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1CNS 1

Conditions

Thrombocytosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Specimen Handling 3Biopsy 3venetoclax 2selinexor 2luspatercept 2Tacrolimus 2Lymphatic Irradiation 2Imatinib Mesylate 2Busulfan 2Azacitidine 2trametinib 1tagraxofusp 1peginterferon alfa-2b 1olutasidenib 1nilotinib 1flumatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1dabrafenib 1Tyrosine Kinase Inhibitors 1Thiotepa 1Spectroscopy, Near-Infrared 1Sirolimus 1Single-Cell Gene Expression Analysis 1Resistance Training 1Receptors, Antigen, T-Cell 1Quality of Life 1Pleurodesis 1Phlebotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × peginterferon alfa-2b × Myeloid × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡